Boston Scientific rose more than 11 percent Wednesday after the firm reported better-than-expected quarterly results, boosted by a strong cardiovascular business.
The stock also hit its highest levels in almost 10 years and was on pace for its best daily performance since Feb. 18
Sales in the company's cardiovascular business, which is also its biggest and includes catheters and heart stents, rose 11 percent to $790 million in the first quarter
Boston Scientific posted earnings per share of 28 cents, excluding items, on revenue of $1.96 billion. Analysts polled by Reuters expected the firm to report earnings per share of 24 cents and revenue of $1.91 billion.